Microbot Medical Doubles Revenue and Customer Base in Q2 2026
Event summary
- Microbot Medical reported over 100% revenue and customer growth in Q2 2026 compared to Q1 2026.
- Procedure volume increased due to site expansion and more users adopting the LIBERTY System.
- Sales territories expanded from 4 to 8, with plans to reach 12 by year-end.
- Received marketing clearance for the LIBERTY System in Israel, the first international approval.
- Entered into an agreement to establish a second manufacturing site to meet growing demand.
The big picture
Microbot Medical's strong Q2 2026 performance highlights the growing demand for advanced robotic technology in endovascular procedures. The company's strategic moves, including expanding sales territories and securing international approvals, position it well to capitalize on broader industry trends toward precision and efficiency in medical interventions. The establishment of a second manufacturing site underscores its commitment to scaling operations to meet future demand.
What we're watching
- Market Expansion
- Whether Microbot Medical can sustain its rapid growth as it enters international markets by the end of 2026.
- Operational Scaling
- The pace at which the company can scale manufacturing to meet increasing demand without compromising quality.
- Regulatory Approvals
- How quickly Microbot Medical can secure additional international regulatory clearances to expand its global footprint.
Related topics